5.9% of cells co-expressed BTN2A1/BTN3A1, suggesting that Vδ2 T cells with full functional capacity could potentially target 32.7% of cells in the tumor if unhindered by the presence of PD-L1 or blocked by αPD-1. The gene discussed is BTN3A1; the disease is neoplasm.